Gateway Investment Advisers LLC Purchases 1,222 Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Gateway Investment Advisers LLC increased its position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 19.8% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 7,383 shares of the biopharmaceutical company’s stock after acquiring an additional 1,222 shares during the quarter. Gateway Investment Advisers LLC’s holdings in Alnylam Pharmaceuticals were worth $1,737,000 at the end of the most recent quarter.

Other large investors also recently modified their holdings of the company. Los Angeles Capital Management LLC raised its stake in Alnylam Pharmaceuticals by 11,433.4% in the third quarter. Los Angeles Capital Management LLC now owns 137,017 shares of the biopharmaceutical company’s stock valued at $37,684,000 after purchasing an additional 135,829 shares in the last quarter. Sanctuary Advisors LLC purchased a new stake in Alnylam Pharmaceuticals in the second quarter valued at approximately $578,000. Toronto Dominion Bank raised its stake in Alnylam Pharmaceuticals by 27.3% in the third quarter. Toronto Dominion Bank now owns 15,466 shares of the biopharmaceutical company’s stock valued at $4,254,000 after purchasing an additional 3,315 shares in the last quarter. Connor Clark & Lunn Investment Management Ltd. raised its stake in Alnylam Pharmaceuticals by 22.4% in the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 73,320 shares of the biopharmaceutical company’s stock valued at $20,165,000 after purchasing an additional 13,422 shares in the last quarter. Finally, Parkman Healthcare Partners LLC purchased a new stake in Alnylam Pharmaceuticals in the third quarter valued at approximately $7,009,000. 92.97% of the stock is currently owned by institutional investors.

Insider Transactions at Alnylam Pharmaceuticals

In other news, EVP Tolga Tanguler sold 1,469 shares of the company’s stock in a transaction dated Tuesday, November 26th. The shares were sold at an average price of $250.98, for a total transaction of $368,689.62. Following the completion of the sale, the executive vice president now owns 13,191 shares of the company’s stock, valued at $3,310,677.18. This represents a 10.02 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CMO Pushkal Garg sold 1,752 shares of the company’s stock in a transaction dated Thursday, December 12th. The shares were sold at an average price of $251.00, for a total transaction of $439,752.00. Following the sale, the chief marketing officer now directly owns 15,705 shares of the company’s stock, valued at $3,941,955. The trade was a 10.04 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 10,122 shares of company stock valued at $2,540,455 in the last quarter. 1.50% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

A number of brokerages recently weighed in on ALNY. William Blair reaffirmed an “outperform” rating on shares of Alnylam Pharmaceuticals in a research note on Tuesday, November 19th. Wolfe Research downgraded shares of Alnylam Pharmaceuticals from a “peer perform” rating to an “underperform” rating in a research note on Tuesday, November 12th. Sanford C. Bernstein decreased their price target on shares of Alnylam Pharmaceuticals from $314.00 to $310.00 and set an “outperform” rating on the stock in a research note on Tuesday, January 7th. Needham & Company LLC reissued a “buy” rating and set a $320.00 price target on shares of Alnylam Pharmaceuticals in a research note on Monday, January 13th. Finally, Piper Sandler reissued an “overweight” rating and set a $296.00 price target on shares of Alnylam Pharmaceuticals in a research note on Monday, November 18th. One investment analyst has rated the stock with a sell rating, six have given a hold rating and nineteen have issued a buy rating to the company’s stock. According to data from MarketBeat.com, Alnylam Pharmaceuticals has an average rating of “Moderate Buy” and a consensus price target of $298.61.

Alnylam Pharmaceuticals Price Performance

ALNY opened at $246.27 on Friday. The stock has a 50-day moving average price of $246.62 and a 200-day moving average price of $259.70. The company has a debt-to-equity ratio of 31.64, a current ratio of 2.75 and a quick ratio of 2.69. The firm has a market cap of $31.76 billion, a PE ratio of -94.00 and a beta of 0.34. Alnylam Pharmaceuticals, Inc. has a 1 year low of $141.98 and a 1 year high of $304.39.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last posted its quarterly earnings results on Thursday, October 31st. The biopharmaceutical company reported ($0.87) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.51) by ($0.36). The firm had revenue of $500.90 million during the quarter, compared to analysts’ expectations of $532.91 million. Alnylam Pharmaceuticals’s revenue was down 33.3% compared to the same quarter last year. During the same period in the previous year, the company posted $1.15 earnings per share. Sell-side analysts predict that Alnylam Pharmaceuticals, Inc. will post -2.21 earnings per share for the current fiscal year.

Alnylam Pharmaceuticals Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.